Vicki Seyfert-Margolis, CEO and Founder of My Own Med, Inc., has published and presented in top journals and numerous conferences about the transformative nature of digital technologies and novel clinical trial designs. Prior to founding My Own Med, Inc., Vicki was appointed in the Obama Administration as the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she worked on a myriad of regulatory and leading-edge science issues, including mobile technologies, innovation in drug development, companion diagnostics, and a whole range of regulatory science initiatives and policies working with industry and academic leaders. Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading-edge assay development and centralized laboratory facilities. Over the course of her career, including time at ITN, she designed and implemented over 35 innovative Phase II and registration clinical trials incorporating biomarker discovery and qualification. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine, and her post- doctoral fellowship work at Harvard University and the National Cancer Institute. Vicki also serves on Board of Directors for the EveryLife Foundation for Rare Diseases, and Eureka Institute for Translational Medicine.